TL;DR: Step Therapy asks members to try safe, lower-cost drugs before a plan covers a more expensive option, when that approach fits the clinical situation. For employers facing steep pharmacy trend, especially from GLP-1s and other specialty medications, Step Therapy can be a practical cost-control tool. The value depends on design. Savings can be meaningful, often modeled in the 20% to 25% range for targeted drug classes, but only if the plan pairs cost rules with clear communication, fair exceptions, and strong clinical review.
Key Takeaways #
- Step Therapy can reduce unnecessary pharmacy spend when lower-cost options work just as well.
- It has become more common in high-cost categories, especially GLP-1 drugs.
- It should never block Medically Necessary care or trap members in a slow process.
- The best programs explain the rules before employees need the drug.
- Leaders should track employee experience, time to therapy, and total plan impact, not drug spend alone.
Drug costs can rise fast and quietly. One new therapy class can shift a plan budget in a single renewal cycle.
That is why HR, finance, and executive teams are paying more attention to pharmacy design. Step Therapy sits at the center of that discussion because it can control spend without treating every member the same. Done well, it helps a plan pay for the right drug at the right time. Done poorly, it creates delays, confusion, and distrust.
How Step Therapy works in an employer health plan #
In plain English, Step Therapy means a health plan asks a member to start with a proven, lower-cost drug before moving to a more expensive one. The plan applies that rule only when the lower-cost option is clinically appropriate.
This often sits inside the pharmacy benefit, alongside Formulary tiers and prior authorization. The goal is simple. Use benefits data in a way leaders can act on, instead of burying decisions in rows of claim detail. That aligns with JA’s view that pharmacy strategy should be clear, measurable, and useful for real decisions.
Step Therapy does not mean “no” forever. A well-built program allows the higher-cost drug when the first option fails, causes side effects, or does not fit the member’s medical history. That point matters because the program should manage waste, not ignore care needs.
For employers dealing with specialty trend, step therapy for expensive medications is one part of a broader pharmacy plan. It works best when the drug class has sound first-line options, clear evidence, and a fast review process.
What happens first, and when a higher-cost drug is approved #
The process is usually straightforward:
- The plan identifies a first-line drug that is safe, effective, and lower in cost.
- The member tries that drug for a defined period, or the prescriber documents why it is not appropriate.
- The plan reviews clinical response, side effects, and Adherence.
- If the lower-cost option fails or is not suitable, the plan approves the higher-cost drug.
That is the ideal flow. The plan should also honor past treatment failure and avoid making employees repeat drugs that already failed under another plan.
Why GLP-1 drugs have made Step Therapy a bigger issue #
GLP-1 demand changed the pharmacy conversation. These drugs can be effective, but they are also expensive, and long-Term use raises the stakes for plan budgets.
KFF’s 2025 employer survey found that 20% of large employers covered GLP-1s mainly for weight loss. Among very large employers, coverage was much higher. Mercer and SHRM also point to GLP-1s as a major factor behind rising employer health costs heading into 2026. Public 2026 data on exact employer Step Therapy adoption is still limited, but the trend is clear. Employers are tightening pharmacy rules around high-cost drugs.
Many plan discussions cite 2025 use of Step Therapy for high-cost drugs at about 60%. The safer conclusion is that Step Therapy is now a common response to GLP-1 pressure, even when public source data does not pin down one exact 2026 number.
Where Step Therapy can lower costs, and where it can go wrong #
Step Therapy can help because pharmacy waste is rarely random. It often shows up when a plan pays brand or specialty prices before testing whether a lower-cost option would work. If a generic, biosimilar, or older brand can deliver the same clinical benefit, the plan should know that before it spends more.
That discipline can improve budget predictability. It can also support better Formulary management and cleaner PBM oversight. Recent attention to PBM rebate disclosures in OBBBA shows why transparency matters. Employers need to know whether pharmacy rules are reducing Net Cost or simply shifting where money flows.
Still, Step Therapy can backfire. A poorly designed program can delay treatment, frustrate employees, and increase admin work for HR and providers. In some cases, restrictions can lead to lower Adherence or higher discontinuation. When that happens, the plan may save on one claim and lose on the bigger picture through avoidable medical costs, missed work, and lower trust.
Step Therapy works when it supports sound care first and cost control second, in that order.
The savings opportunity for employers facing rising pharmacy spend #
The commonly cited 20% to 25% savings range is best used as a planning benchmark, not a promise. Savings depend on the drug class, member mix, plan rules, and how often exceptions apply.
For example, Step Therapy may work well in a class where a low-cost first-line drug has strong evidence and broad tolerance. It will have less impact when the lower-cost option fails often or fits only a narrow group. That is why leaders should judge Step Therapy inside total plan performance, not unit drug price alone.
A good question for finance is not “Did we spend less on one drug?” It is “Did we improve total pharmacy value without harming care?”
The employee experience risks leaders should not ignore #
Employees feel pharmacy rules at stressful moments, often when a doctor has already recommended a drug. If the process is confusing, the plan can look cold and purely cost-driven.
That risk is real. Research on Formulary restrictions has shown higher discontinuation in some settings. Members may give up, delay treatment, or pay out of pocket. Meanwhile, HR teams often absorb the frustration through appeals, payroll questions, and Open Enrollment concerns.
The human side matters. A parent managing diabetes, or an employee trying to address obesity and heart risk, does not experience Step Therapy as a spreadsheet exercise. The rule lands in daily life, at home and at work.
How to build a Step Therapy program employees will actually trust #
Trust starts with design. Leaders should build the rule around clinical evidence, member support, and speed. If any one of those is weak, the program will struggle.
That means the pharmacy partner, plan sponsor, and clinicians need shared rules from the start. Which drugs require a first step? How long is the review period? What counts as treatment failure? When can a prescriber bypass the step? Those answers should be settled before the plan goes live.
This is also where a human-centered view matters. Pharmacy strategy affects families, not only claims. When a program respects that reality, it has a better chance of producing measurable outcomes and stronger ROR, return on relationship.
Start with clear communication, before employees hit the pharmacy counter #
Most employee anger comes from surprise. If the first time someone hears about Step Therapy is at the pharmacy, the plan has already lost ground.
Communication should start during Open Enrollment and continue all year. Use plain-language drug lists, short FAQs, and examples of how the process works. Explain why the rule exists. Keep the message honest: the plan wants to control unnecessary cost, but it also wants members to get effective care.
Member advocacy support also helps. Employees should know where to call, what paperwork may be needed, and how long a review usually takes. That support matters as much as the rule itself.
The same principle applies during renewal planning. Pharmacy rules should be part of broader cost discussions, including PBM renewal negotiation tips and plan forecasting.
Use clinical guardrails and a fast exception process #
Clinical guardrails protect both the plan and the member. They should define when Step Therapy applies and when it should not.
For example, exceptions should move quickly when a member has already tried the first-line drug, when the physician documents medical necessity, or when delay could cause harm. Prior authorization and Step Therapy also need to work together. If they are handled in separate silos, employees get stuck.
Fast, fair review is the difference between sensible management and red tape. Plans should set target turnaround times, allow electronic physician submissions, and train service teams to resolve cases without repeat paperwork.
Speed matters because employees do not measure a process by policy language. They measure it by how long it takes to start treatment.
What smart employers should measure after launch #
A Step Therapy program should never run on autopilot. Leaders need a short scorecard that shows whether the rule is helping or hurting.
This kind of review works best when the data is easy to read and tied to action. A clean scorecard beats a 40-tab spreadsheet every time.
Here is a practical set of measures to review each quarter:
| Metric | What it tells you |
|---|---|
| Drug spend trend | Whether targeted categories are stabilizing |
| Step edit approval rate | How often first-line therapy is working |
| Exception rate | Whether rules are too rigid or clinically misaligned |
| Time to therapy | How quickly members reach appropriate treatment |
| Complaints and appeals | Where confusion or friction is building |
| Adherence and persistence | Whether members stay on treatment after the step |
The goal is balance. Lower spend is useful, but lower spend with higher abandonment is not a win.
Look beyond pharmacy savings to measure real plan outcomes #
Employers should also track medical trend, absence patterns, and support needs tied to affected populations. A pharmacy rule that lowers claims but increases downstream cost is a weak trade.
That wider view is where ROR becomes useful. A strong plan supports the business and the people in it. When leaders measure both, they get a truer read on value.
Step Therapy can help control drug costs, especially in high-cost classes like GLP-1s. Its strength comes from discipline, not from blunt restrictions.
The better approach is clear. Build the rule with transparency, clinical oversight, and fast support for exceptions. Then measure what happens after launch.
HR, finance, and executive teams do not need a pharmacy program that only looks efficient on paper. They need one that holds up over time, protects employee care, and stays flexible as drug trends change.
